NanoViricides, Inc. (NNVC)Healthcare | Biotechnology | Shelton, United States | NYSE American
1.37 USD
+0.21
(18.104%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 1.37 Short-term: ★★★★★ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:13 a.m. EDT
Huge short-term bullish momentum play with $160M catalyst potential; short-term rating is 5 stars as speculators are positioning for a move away from current lows, though fundamentals remain volatile with negative earnings expected. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.089546 |
| AutoETS | 0.089548 |
| MSTL | 0.091570 |
| AutoTheta | 0.150077 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.98 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.715 |
| Excess Kurtosis | -0.47 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 29,585,150 |
| Forward P/E | -3.91 |
| Beta | 1.30 |
| Website | https://www.nanoviricides.com |
As of April 19, 2026, 12:13 a.m. EDT: Options flow shows overwhelming speculative bullishness with virtually zero put activity. Call volume is heavily skewed toward out-of-the-money strikes (2.5, 5.0, 7.5) representing significant upside positioning. The skew heavily favors calls over all expirations, indicating a 'labour supply' or asymmetric bet on price appreciation rather than downside protection.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.05384612 |
| Address1 | 1 Controls Drive |
| All Time High | 262.5 |
| All Time Low | 0.85 |
| Ask | 1.37 |
| Ask Size | 8,500 |
| Average Daily Volume10 Day | 253,920 |
| Average Daily Volume3 Month | 253,888 |
| Average Volume | 253,888 |
| Average Volume10Days | 253,920 |
| Beta | 1.296 |
| Bid | 1.3 |
| Bid Size | 900 |
| Book Value | 0.513 |
| City | Shelton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.37 |
| Current Ratio | 4.429 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.38 |
| Day Low | 1.16 |
| Display Name | NanoViricides |
| Dividend Date | 1,569,283,200 |
| Earnings Timestamp End | 1,747,339,200 |
| Earnings Timestamp Start | 1,747,339,200 |
| Ebitda | -7,776,407 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.142 |
| Enterprise Value | 24,434,580 |
| Eps Current Year | -0.35 |
| Eps Forward | -0.35 |
| Eps Trailing Twelve Months | -0.49 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.0188 |
| Fifty Day Average Change | 0.35119998 |
| Fifty Day Average Change Percent | 0.34471926 |
| Fifty Two Week Change Percent | 5.384612 |
| Fifty Two Week High | 2.23 |
| Fifty Two Week High Change | -0.86 |
| Fifty Two Week High Change Percent | -0.38565022 |
| Fifty Two Week Low | 0.85 |
| Fifty Two Week Low Change | 0.52 |
| Fifty Two Week Low Change Percent | 0.61176467 |
| Fifty Two Week Range | 0.85 - 2.23 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,130,333,400,000 |
| Float Shares | 19,626,616 |
| Forward Eps | -0.35 |
| Forward P E | -3.914286 |
| Free Cashflow | -4,385,204 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 7 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.028010001 |
| Held Percent Institutions | 0.14389 |
| Implied Shares Outstanding | 21,595,000 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,751,241,600 |
| Last Split Date | 1,569,283,200 |
| Last Split Factor | 1:20 |
| Long Business Summary | NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut. |
| Long Name | NanoViricides, Inc. |
| Market | us_market |
| Market Cap | 29,585,150 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_22594191 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -8,318,441 |
| Next Fiscal Year End | 1,782,777,600 |
| Non Diluted Market Cap | 29,585,150 |
| Number Of Analyst Opinions | 2 |
| Open | 1.18 |
| Operating Cashflow | -7,336,383 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 203 937 6137 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 1.37 |
| Post Market Time | 1,776,470,271 |
| Previous Close | 1.16 |
| Price Eps Current Year | -3.914286 |
| Price Hint | 4 |
| Price To Book | 2.6705654 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.307 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.21 |
| Regular Market Change Percent | 18.1035 |
| Regular Market Day High | 1.38 |
| Regular Market Day Low | 1.16 |
| Regular Market Day Range | 1.16 - 1.38 |
| Regular Market Open | 1.18 |
| Regular Market Previous Close | 1.16 |
| Regular Market Price | 1.37 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 633,790 |
| Return On Assets | -0.44019002 |
| Return On Equity | -0.77531 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 21,595,000 |
| Shares Percent Shares Out | 0.035 |
| Shares Short | 756,215 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 962,990 |
| Short Name | NanoViricides, Inc. |
| Short Percent Of Float | 0.036 |
| Short Ratio | 3.31 |
| Source Interval | 15 |
| State | CT |
| Symbol | NNVC |
| Target High Price | 7.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 6.5 |
| Target Median Price | 6.5 |
| Total Cash | 5,150,580 |
| Total Cash Per Share | 0.239 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.49 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.30525 |
| Two Hundred Day Average Change | 0.064749956 |
| Two Hundred Day Average Change Percent | 0.049607318 |
| Type Disp | Equity |
| Volume | 633,790 |
| Website | https://www.nanoviricides.com |
| Zip | 6,484 |